SCN1a gene mutation is not completely curable, and the corresponding gene mutation is mainly prone to Dravet syndrome, which manifests itself as an epileptic syndrome with onset in infancy and early childhood, with a variety of seizures and associated mental retardation.
The SCN1a gene mutation itself is a chromosomal abnormality that triggers Dravet syndrome, which is characterized by febrile convulsions, myoclonus, and, in severe cases, coma. The corresponding disease can only be controlled by reducing stimulation, regular use of medication (levetiracetam, etc.) to minimize the number of episodes, because of the close relationship with genetic factors, and is not completely curable.
Once the corresponding gene mutation causes seizures, it is necessary to consult a doctor in time for observation, and after confirming the diagnosis of the corresponding disease, to carry out standardized treatment under the guidance of the clinician to mitigate the damage.